Accessibility

Our global life sciences company brings diagnostic testing & drug development together.

Labcorp.com

Itraconazole, Serum or Plasma

CPT: 80189

Synonyms

  • Sporanox®

Specimen Requirements


Specimen

Serum (preferred) or plasma


Volume

1 mL


Minimum Volume

0.5 mL


Container

Red-top tube or lavender-top (EDTA) tube


Collection

Transfer separated serum or plasma to a plastic transport tube. Do not use a gel barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage times, the decrease in drug level due to absorption may be clinically significant.


Storage Instructions

Refrigerate. Stable for 14 days at room temperature, refrigerated, or frozen.


Stability Requirements

Temperature

Period

Room temperature

14 days

Refrigerated

14 days

Frozen

14 days


Causes for Rejection

Gel barrier tubes


Test Details


Use

Treatment of susceptible fungal infections in immunocompromised and immunocompetent patients including blastomycosis and histoplasmosis; indicated for aspergillosis and onychomycosis of the toenail and fingernail. It has been recommended that routine monitoring occur during the first week of therapy to ensure therapeutic levels are achieved for each individual and to continue monitoring if clinical presentations do not improve or decline.


Limitations

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.


Methodology

Liquid chromatography/tandem mass spectrometry (LC/MS-MS)


References

Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014 May;69(5):1162-1176.24379304
Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob Agents Chemother. 2009 Jan;53(1):24-34.18955533
Clinical Primer: Potential Hepatic Complications With Triazole Therapy. Tinton Falls, NJ: Fallon Medica LLC; 2010.

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf